title: Beta-tricalcium phosphate and basic fibroblast growth factor combination enhances periodontal regeneration in intrabony defects in dogs.
abstract: The combined effect of beta-tricalcium phosphate and basic fibroblast growth factor was observed in the regeneration of periodontal tissue in dogs. For this purpose, either beta-TCP and FGF-2 (beta-TCP/FGF-2 group) or FGF-2 alone (FGF-2 group) was applied in intrabony defects. The control group received beta-TCP alone. The tissues were histologically examined at 2, 4, or 8 weeks following treatment. The control group was characterized by incomplete, newly formed bone around beta-TCP particles. The beta-TCP/FGF-2 group showed a statistically significant increase in both new bone and cementum formation compared to the FGF-2-alone group (76.3% vs. 65.3%, p < 0.01; 81.0% vs. 68.3%, p < 0.01, respectively). These findings suggested that beta-TCP may be a suitable scaffold for FGF-2 and that the combination of beta-TCP and FGF-2 can enhance bone and cementum formation.
authors.affiliation: Department of Periodontology, Tokyo Dental College, 1-2-2 Masago, Mihama-ku, Chiba-shi, Chiba 261-8502, Japan. yooi@tdc.ac.jp
authors.forename: Yosei
authors.initials: Y
authors.lastname: Oi
authors.forename: Mikio
authors.initials: M
authors.lastname: Ota
authors.forename: Shigeki
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Shibukawa
authors.forename: Satoru
authors.initials: S
authors.lastname: Yamada
mesh_terms: D000135:Acid Phosphatase / Q000032:analysis; D016301:Alveolar Bone Loss / Q000473:pathology / Q000601:surgery*; D000539:Alveolar Process / Q000473:pathology; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D001861:Bone Regeneration / Q000502:physiology*; D018786:Bone Substitutes / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D025021:Cementogenesis / Q000502:physiology; D003238:Connective Tissue / Q000473:pathology; D003739:Dental Cementum / Q000473:pathology; D004285:Dogs; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D007527:Isoenzymes / Q000032:analysis; D008297:Male; D008855:Microscopy, Electron, Scanning; D018919:Neovascularization, Physiologic / Q000502:physiology; D010012:Osteogenesis / Q000502:physiology; D016062:Porosity; D011897:Random Allocation; D013524:Surgical Flaps; D000071681:Tartrate-Resistant Acid Phosphatase; D013997:Time Factors; D054457:Tissue Scaffolds; D019237:Tooth Cervix / Q000473:pathology
chemical_list: D015415:Biomarkers; D018786:Bone Substitutes; D002130:Calcium Phosphates; D007527:Isoenzymes; C485817:beta-tricalcium phosphate; D016222:Fibroblast Growth Factor 2; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase